Publication | Closed Access

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

HepatologyBevacizumab BiosimilarMedicinePathologyVersus SorafenibLiver CancerCancer TreatmentOncologyRadiation OncologyUnresectable Hepatocellular CarcinomaHepatocellular Carcinoma